LINC01023 Promotes the Hepatoblastoma Tumorigenesis via miR-378a-5p/WNT3 Axis.
Hepatoblastoma
LINC01023
WNT3
lncRNA
miR-378a-5p
Journal
Molecular and cellular biochemistry
ISSN: 1573-4919
Titre abrégé: Mol Cell Biochem
Pays: Netherlands
ID NLM: 0364456
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
21
01
2022
accepted:
07
12
2022
medline:
16
6
2023
pubmed:
29
12
2022
entrez:
28
12
2022
Statut:
ppublish
Résumé
Hepatoblastoma is the most common type of hepatic tumors occurring in children between 0 and 5 years. And the exact pathophysiology of the disease is still mysterious. Accumulating studies on LncRNA have shown its pivotal role in the development and progression of distinct human cancers. However, the role of LINC01023 in hepatoblastoma is unknown. The relative expression of LINC01023, miR-378a-5p, and Wnt3 on hepatoblastoma tissue and cell lines was determined by quantitative polymerase chain reaction (qRT-PCR). The effect of LINC01023 downregulation and upregulation on cell proliferation, colony formation and apoptosis activities in HUH6 and HepG2 Cells was assessed by CKK8, clonogenic and flow cytometry analysis, respectively. Dual luciferase, RNA immunoprecipitation (RIP), and RNA pull-down were performed to confirm the interaction between LINC01023 and miR-378a-5p. Similarly, Dual luciferase assay was performed to confirmed the interaction between Wnt3 and miR-378a-5p. The xenograft tumorgenicity test was performed to elucidate the tumorgenicity potential of LINC01023. LINC01023 was significantly upregulated in hepatoblastoma tissue and cell lines rather than in adjacent normal hepatic tissue and QSG7701 cell lines. LINC01023 silencing attenuated cell proliferation, colony formation and increased cell apoptosis. Conversely, LINC01023 upregulation results in significant increase in cell proliferation, and colony formation activities however, a significant reduction in apoptosis activity was reported. Interaction between the LINC01023 and WNT3 was confirmed by dual luciferase assay. Xenograft animal tumorgenicity test confirmed the in-vivo tumorigenesis potential of LINC01203. To the best of our knowledge, this study is the first study demonstrating the role of LINC01023 in hepatoblastoma tumorigenesis through the LINC01023/miR-378a-5p/Wnt3 axis. It could be a potential therapeutic target and a prognostic biomarker in hepatoblastoma.
Identifiants
pubmed: 36576714
doi: 10.1007/s11010-022-04636-5
pii: 10.1007/s11010-022-04636-5
doi:
Substances chimiques
MicroRNAs
0
WNT3 protein, human
0
Wnt3 Protein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1867-1885Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Smith WL, Franken EA, Mitros FA (1983) Liver tumors in children. Semin Roentgenol 18:136–148. https://doi.org/10.1016/0037-198x(83)90014-7
doi: 10.1016/0037-198x(83)90014-7
pubmed: 6306839
Meyers RL (2007) Tumors of the liver in children. Surg Oncol 16:195–203. https://doi.org/10.1016/j.suronc.2007.07.002
doi: 10.1016/j.suronc.2007.07.002
pubmed: 17714939
Bell D, Ranganathan S, Tao J, Monga SP (2017) Novel advances in understanding of molecular pathogenesis of hepatoblastoma: a Wnt/β-catenin perspective. Gene Expr 17:141–154. https://doi.org/10.3727/105221616x693639
doi: 10.3727/105221616x693639
pubmed: 27938502
Sharma D, Subbarao G, Saxena R (2017) Hepatoblastoma. Semin Diagn Pathol 34:192–200. https://doi.org/10.1053/j.semdp.2016.12.015
doi: 10.1053/j.semdp.2016.12.015
pubmed: 28126357
Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL (2014) Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 26:19–28. https://doi.org/10.1097/mop.0000000000000046
doi: 10.1097/mop.0000000000000046
pubmed: 24322718
Trobaugh-Lotrario AD, López-Terrada D, Li P, Feusner JH (2018) Hepatoblastoma in patients with molecularly proven familial adenomatous polyposis: clinical characteristics and rationale for surveillance screening. Pediatr Blood Cancer 65:e27103. https://doi.org/10.1002/pbc.27103
doi: 10.1002/pbc.27103
pubmed: 29719120
Puchmajerová A, Křepelová A, Indráková J, Sítková R, Balaščak I, Kruseová J, Švojgr K, Kodet R, Kynčl M, Vícha A, Macek M Jr (2016) Hepatoblastoma, etiology, case reports. Klin Onkol 29(Suppl 1):S78-82. https://doi.org/10.14735/amko2016s78
doi: 10.14735/amko2016s78
pubmed: 26691946
Mamlok V, Nichols M, Lockhart L, Mamlok R (1989) Trisomy 18 and hepatoblastoma. Am J Med Genet 33:125–126. https://doi.org/10.1002/ajmg.1320330119
doi: 10.1002/ajmg.1320330119
pubmed: 2546426
Herzog CE, Andrassy RJ, Eftekhari F (2000) Childhood cancers: hepatoblastoma. Oncologist 5:445–453. https://doi.org/10.1634/theoncologist.5-6-445
doi: 10.1634/theoncologist.5-6-445
pubmed: 11110595
Russell JO, Monga SP (2018) Wnt/β-catenin signaling in liver development, homeostasis, and pathobiology. Annu Rev Pathol 13:351–378. https://doi.org/10.1146/annurev-pathol-020117-044010
doi: 10.1146/annurev-pathol-020117-044010
pubmed: 29125798
Zhan T, Rindtorff N, Boutros M (2017) Wnt signaling in cancer. Oncogene 36:1461–1473. https://doi.org/10.1038/onc.2016.304
doi: 10.1038/onc.2016.304
pubmed: 27617575
Mavila N, Thundimadathil J (2019) The emerging roles of cancer stem cells and Wnt/beta-catenin signaling in hepatoblastoma. Cancers (Basel). https://doi.org/10.3390/cancers11101406
doi: 10.3390/cancers11101406
pubmed: 31547062
He S, Tang S (2020) WNT/β-catenin signaling in the development of liver cancers. Biomed Pharmacother 132:110851. https://doi.org/10.1016/j.biopha.2020.110851
doi: 10.1016/j.biopha.2020.110851
pubmed: 33080466
Kim M, Lee HC, Tsedensodnom O, Hartley R, Lim YS, Yu E, Merle P, Wands JR (2008) Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol 48:780–791. https://doi.org/10.1016/j.jhep.2007.12.020
doi: 10.1016/j.jhep.2007.12.020
pubmed: 18313787
pmcid: 2390890
Nakashima N, Liu D, Huang CL, Ueno M, Zhang X, Yokomise H (2012) Wnt3 gene expression promotes tumor progression in non-small cell lung cancer. Lung Cancer 76:228–234. https://doi.org/10.1016/j.lungcan.2011.10.007
doi: 10.1016/j.lungcan.2011.10.007
pubmed: 22070884
Nambotin SB, Tomimaru Y, Merle P, Wands JR, Kim M (2012) Functional consequences of WNT3/Frizzled7-mediated signaling in non-transformed hepatic cells. Oncogenesis 1:e31. https://doi.org/10.1038/oncsis.2012.31
doi: 10.1038/oncsis.2012.31
pubmed: 23552403
pmcid: 3503290
Anastas JN, Moon RT (2013) WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer 13:11–26. https://doi.org/10.1038/nrc3419
doi: 10.1038/nrc3419
pubmed: 23258168
Sha YL, Liu S, Yan WW, Dong B (2019) Wnt/β-catenin signaling as a useful therapeutic target in hepatoblastoma. Biosci Rep. https://doi.org/10.1042/bsr20192466
Ransohoff JD, Wei Y, Khavari PA (2018) The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol 19:143–157. https://doi.org/10.1038/nrm.2017.104
doi: 10.1038/nrm.2017.104
pubmed: 29138516
Ulitsky I, Bartel DP (2013) lincRNAs: genomics, evolution, and mechanisms. Cell 154:26–46. https://doi.org/10.1016/j.cell.2013.06.020
doi: 10.1016/j.cell.2013.06.020
pubmed: 23827673
pmcid: 3924787
Deniz E, Erman B (2017) Long noncoding RNA (lincRNA), a new paradigm in gene expression control. Funct Integr Genomics 17:135–143. https://doi.org/10.1007/s10142-016-0524-x
doi: 10.1007/s10142-016-0524-x
pubmed: 27681237
Tang SS, Zheng BY, Xiong XD (2015) LincRNA-p21: implications in human diseases. Int J Mol Sci 16:18732–18740. https://doi.org/10.3390/ijms160818732
doi: 10.3390/ijms160818732
pubmed: 26270659
pmcid: 4581268
Tian X, Wu Y, Yang Y, Wang J, Niu M, Gao S, Qin T, Bao D (2020) Long noncoding RNA LINC00662 promotes M2 macrophage polarization and hepatocellular carcinoma progression via activating Wnt/β-catenin signaling. Mol Oncol 14:462–483. https://doi.org/10.1002/1878-0261.12606
doi: 10.1002/1878-0261.12606
pubmed: 31785055
Yu M, Yu S, Gong W, Chen D, Guan J, Liu Y (2019) Knockdown of linc01023 restrains glioma proliferation, migration and invasion by regulating IGF-1R/AKT pathway. J Cancer 10:2961–2968. https://doi.org/10.7150/jca.31004
doi: 10.7150/jca.31004
pubmed: 31281473
pmcid: 6590038
Nagae G, Yamamoto S, Fujita M, Fujita T, Nonaka A, Umeda T, Fukuda S, Tatsuno K, Maejima K, Hayashi A, Kurihara S, Kojima M, Hishiki T, Watanabe K, Ida K, Yano M, Hiyama Y, Tanaka Y, Inoue T, Ueda H, Nakagawa H, Aburatani H, Hiyama E (2021) Genetic and epigenetic basis of hepatoblastoma diversity. Nat Commun 12:5423. https://doi.org/10.1038/s41467-021-25430-9
doi: 10.1038/s41467-021-25430-9
pubmed: 34538872
pmcid: 8450290
Zhang B, Pan X, Cobb GP, Anderson TA (2007) microRNAs as oncogenes and tumor suppressors. Dev Biol 302:1–12. https://doi.org/10.1016/j.ydbio.2006.08.028
doi: 10.1016/j.ydbio.2006.08.028
pubmed: 16989803
Ruan K, Fang X, Ouyang G (2009) MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 285:116–126. https://doi.org/10.1016/j.canlet.2009.04.031
doi: 10.1016/j.canlet.2009.04.031
pubmed: 19464788
Pan X, Zhao L, Quan J, Liu K, Lai Y, Li Z, Zhang Z, Xu J, Xu W, Guan X, Li H, Yang S, Gui Y, Chen Y, Lai Y (2019) MiR-378a-5p acts as a tumor suppressor in renal cell carcinoma and is associated with the good prognosis of patients. Am J Transl Res 11:2207–2218
pubmed: 31105829
pmcid: 6511777
Li K, Zhang J, Zhang M, Wu Y, Lu X, Zhu Y (2021) miR-378a-5p inhibits the proliferation of colorectal cancer cells by downregulating CDK1. World J Surg Oncol 19:54. https://doi.org/10.1186/s12957-021-02166-w
doi: 10.1186/s12957-021-02166-w
pubmed: 33608020
pmcid: 7896405
Tupone MG, D’Aguanno S, Di Martile M, Valentini E, Desideri M, Trisciuoglio D, Donzelli S, Sacconi A, Buglioni S, Ercolani C, Biagioni A, Fibbi G, Fattore L, Mancini R, Ciliberto G, Blandino G, Del Bufalo D (2020) microRNA-378a-5p iS a novel positive regulator of melanoma progression. Oncogenesis 9:22. https://doi.org/10.1038/s41389-020-0203-6
doi: 10.1038/s41389-020-0203-6
pubmed: 32060259
pmcid: 7021836
Zheng S, Li M, Miao K, Xu H (2020) lncRNA GAS5-promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling. J Cell Biochem 121:2225–2235. https://doi.org/10.1002/jcb.29445
doi: 10.1002/jcb.29445
pubmed: 31692053
Huang HY, Chien CH, Jen KH, Huang HD (2006) RegRNA: an integrated web server for identifying regulatory RNA motifs and elements. Nucleic Acids Res 34:W429–W434. https://doi.org/10.1093/nar/gkl333
doi: 10.1093/nar/gkl333
pubmed: 16845041
pmcid: 1538840
Li JH, Liu S, Zhou H, Qu LH, Yang JH (2014) starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res 42:D92–D97. https://doi.org/10.1093/nar/gkt1248
doi: 10.1093/nar/gkt1248
pubmed: 24297251
Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19:92–105. https://doi.org/10.1101/gr.082701.108
doi: 10.1101/gr.082701.108
pubmed: 18955434
pmcid: 2612969
Krüger J, Rehmsmeier M (2006) RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res 34:W451–W454. https://doi.org/10.1093/nar/gkl243
doi: 10.1093/nar/gkl243
pubmed: 16845047
pmcid: 1538877
Liu K, Yan Z, Li Y, Sun Z (2013) Linc2GO: a human LincRNA function annotation resource based on ceRNA hypothesis. Bioinformatics 29:2221–2222. https://doi.org/10.1093/bioinformatics/btt361
doi: 10.1093/bioinformatics/btt361
pubmed: 23793747
Teng PC, Liang Y, Yarmishyn AA, Hsiao YJ, Lin TY, Lin TW, Teng YC, Yang YP, Wang ML, Chien CS, Luo YH, Chen YM, Hsu PK, Chiou SH, Chien Y (2021) RNA modifications and epigenetics in modulation of lung cancer and pulmonary diseases. Int J Mol Sci. https://doi.org/10.3390/ijms221910592
doi: 10.3390/ijms221910592
pubmed: 34884828
pmcid: 8657659
Yue B, Cai D, Liu C, Fang C, Yan D (2016) Linc00152 functions as a competing endogenous RNA to confer oxaliplatin resistance and holds prognostic values in colon cancer. Mol Ther 24:2064–2077. https://doi.org/10.1038/mt.2016.180
doi: 10.1038/mt.2016.180
pubmed: 27633443
pmcid: 5167786
You J, Li J, Ke C, Xiao Y, Lu C, Huang F, Mi Y, Xia R, Li Q (2021) Oncogenic long intervening noncoding RNA Linc00284 promotes c-Met expression by sponging miR-27a in colorectal cancer. Oncogene 40:4151–4166. https://doi.org/10.1038/s41388-021-01839-w
doi: 10.1038/s41388-021-01839-w
pubmed: 34050266
pmcid: 8211564
Zhang Z, Lin W, Lin Y, Kang M, Zhu J, Tong Z, Wu L, Sun J, Lin J (2021) Long intergenic non-coding RNA Linc00485 promotes lung cancer progression by modulating miR-298/c-Myc axis. J Cell Mol Med 25:309–322. https://doi.org/10.1111/jcmm.16036
doi: 10.1111/jcmm.16036
pubmed: 33237626
Yu Y, Yang J, Li Q, Xu B, Lian Y, Miao L (2017) LINC00152: a pivotal oncogenic long non-coding RNA in human cancers. Cell Prolif. https://doi.org/10.1111/cpr.12349
doi: 10.1111/cpr.12349
pubmed: 29171111
pmcid: 6528870
Hyun J, Wang S, Kim J, Rao KM, Park SY, Chung I, Ha CS, Kim SW, Yun YH, Jung Y (2016) MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression. Nat Commun 7:10993. https://doi.org/10.1038/ncomms10993
doi: 10.1038/ncomms10993
pubmed: 27001906
pmcid: 4804167
Taciak B, Pruszynska I, Kiraga L, Bialasek M, Krol M (2018) Wnt signaling pathway in development and cancer. J Physiol Pharmacol. https://doi.org/10.26402/jpp.2018.2.07
doi: 10.26402/jpp.2018.2.07
pubmed: 29980141
Nie X, Xia F, Liu Y, Zhou Y, Ye W, Hean P, Meng J, Liu H, Liu L, Wen J, Ren X, Chen WD, Wang YD (2019) Downregulation of Wnt3 suppresses colorectal cancer development through inhibiting cell proliferation and migration. Front Pharmacol 10:1110. https://doi.org/10.3389/fphar.2019.01110
doi: 10.3389/fphar.2019.01110
pubmed: 31632267
pmcid: 6779829
Wang HS, Nie X, Wu RB, Yuan HW, Ma YH, Liu XL, Zhang JY, Deng XL, Na Q, Jin HY, Bian YC, Gao YM, Wang YD, Chen WD (2016) Downregulation of human Wnt3 in gastric cancer suppresses cell proliferation and induces apoptosis. Onco Targets Ther 9:3849–3860. https://doi.org/10.2147/ott.S101782
doi: 10.2147/ott.S101782
pubmed: 27390525
pmcid: 4930241